CytomX Therapeutics Inc [NASDAQ: CTMX] gained 13.48% on the last trading session, reaching $1.09 price per share at the time.
If compared to the average trading volume of 2.06M shares, CTMX reached a trading volume of 5654258 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about CytomX Therapeutics Inc [CTMX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $3.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 14, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $2.25 to $3.50. The new note on the price target was released on May 28, 2024, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Wedbush analysts kept a Outperform rating on CTMX stock. On May 06, 2024, analysts increased their price target for CTMX shares from 2.50 to 8.
The Average True Range (ATR) for CytomX Therapeutics Inc is set at 0.09, with the Price to Sales ratio for CTMX stock in the period of the last 12 months amounting to 0.64.
Trading performance analysis for CTMX stock
CytomX Therapeutics Inc [CTMX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.93. With this latest performance, CTMX shares gained by 139.51% in over the last four-week period, additionally plugging by 7.92% over the last 6 months – not to mention a drop of -75.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTMX stock in for the last two-week period is set at 77.80, with the RSI for the last a single of trading hit 83.60, and the three-weeks RSI is set at 71.93 for CytomX Therapeutics Inc [CTMX]. The present Moving Average for the last 50 days of trading for this stock 0.6628, while it was recorded at 0.9567 for the last single week of trading, and 0.9728 for the last 200 days.
CytomX Therapeutics Inc [CTMX]: A deeper dive into fundamental analysis
CytomX Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.25 and a Current Ratio set at 1.25.
An analysis of Institutional ownership at CytomX Therapeutics Inc [CTMX]
The top three institutional holders of CTMX stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 7.79 million shares, which is approximately 9.1799%. JANUS HENDERSON GROUP PLC, holding 6.3 million shares of the stock with an approximate value of $$7.72 million in CTMX stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$6.38 million in CTMX stock with ownership which is approximately 6.1598%.
